Multiparametric Magnetic Resonance Imaging with Targeted-only Biopsy—A New Standard for Guidelines on Prostate Cancer Detection?
In this issue of European Urology, Kasivisvanathan et al [1] report on their timely meta-analysis of two randomized trials comparing prebiopsy magnetic resonance imaging (MRI) with targeted biopsy (TBx) only (ie, no systematic biopsies) versus standard transrectal ultrasound biopsy (TRUS-Bx) in biopsy naïve-men at risk of prostate cancer. The key findings are that the MRI plus TBx was superior to TRUS-Bx in detecting clinically significant cancer by approximately 8% (36.3% vs 27.6%) and reduced diagnosis of low-grade prostate cancer by 12%.
